Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Lingaku Lee, Tetsuhide Ito & Robert T. Jensen. (2018) Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opinion on Pharmacotherapy 19:8, pages 909-928.
Read now
Read now
Michele Ghidini, Fausto Petrelli, Antonio Ghidini, Gianluca Tomasello, Jens Claus Hahne, Rodolfo Passalacqua & Sandro Barni. (2017) Clinical development of mTor inhibitors for renal cancer. Expert Opinion on Investigational Drugs 26:11, pages 1229-1237.
Read now
Read now
Nisha A Mohindra, Francis J Giles & Leonidas C Platanias. (2014) Use of mTOR inhibitors in the treatment of malignancies. Expert Opinion on Pharmacotherapy 15:7, pages 979-990.
Read now
Read now
Articles from other publishers (26)
Iva Srdanovic, Ningning Yang & Sidhartha D Ray. 2024. Encyclopedia of Toxicology. Encyclopedia of Toxicology
685
699
.
Suhail Ahmad Mir, Ashraf Dar, Saad Ali Alshehri, Shadma Wahab, Laraibah Hamid, Mohammad Ali Abdullah Almoyad, Tabasum Ali & Ghulam Nabi Bader. (2023) Exploring the mTOR Signalling Pathway and Its Inhibitory Scope in Cancer. Pharmaceuticals 16:7, pages 1004.
Crossref
Crossref
Arka Das, Gurubasavaraja Swamy Purawarga Matada, Prasad Sanjay Dhiwar, Nulgumnalli Manjunathaiah Raghavendra, Nahid Abbas, Ekta Singh, Abhishek Ghara & Ganesh Prasad Shenoy. (2023) Molecular recognition of some novel mTOR kinase inhibitors to develop anticancer leads by drug-likeness, molecular docking and molecular dynamics based virtual screening strategy. Computational Toxicology 25, pages 100257.
Crossref
Crossref
Guangyang Xu, Meirong Huang, Tao Zhang, Ying Shao, Shengbiao Tang, He Cao, Xinhao Zhang & Jiangtao Sun. (2022) Asymmetric Arylation of Diazoesters with Anisoles Enabled by Cooperative Gold and Phosphoric Acid Catalysis. Organic Letters 24:15, pages 2809-2814.
Crossref
Crossref
Moran Grossman & Elaine Adler. 2021. Protein Kinases - Promising Targets for Anticancer Drug Research. Protein Kinases - Promising Targets for Anticancer Drug Research.
Justyna Jakubowska, Bartłomiej Pawlik, Krystyna Wyka, Małgorzata Stolarska, Katarzyna Kotulska, Sergiusz Jóźwiak, Wojciech Młynarski & Joanna Trelińska. (2021) New Insights into Red Blood Cell Microcytosis upon mTOR Inhibitor Administration. International Journal of Molecular Sciences 22:13, pages 6802.
Crossref
Crossref
Amy K. LeBlanc, Christina N. Mazcko, Aswini Cherukuri, Erika P. Berger, William C. Kisseberth, Megan E. Brown, Susan E. Lana, Kristen Weishaar, Brian K. Flesner, Jeffrey N. Bryan, David M. Vail, Jenna H. Burton, Jennifer L. Willcox, Anthony J. Mutsaers, J. Paul Woods, Nicole C. Northrup, Corey Saba, Kaitlin M. Curran, Haley Leeper, Heather Wilson-Robles, Brandan G. Wustefeld-Janssens, Stephanie Lindley, Annette N. Smith, Nikolaos Dervisis, Shawna Klahn, Mary Lynn Higginbotham, Raelene M. Wouda, Erika Krick, Jennifer A. Mahoney, Cheryl A. London, Lisa G. Barber, Cheryl E. Balkman, Angela L. McCleary-Wheeler, Steven E. Suter, Olya Martin, Antonella Borgatti, Kristine Burgess, Michael O. Childress, Janean L. Fidel, Sara D. Allstadt, Daniel L. Gustafson, Laura E. Selmic, Chand Khanna & Timothy M. Fan. (2021) Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs. Clinical Cancer Research 27:11, pages 3005-3016.
Crossref
Crossref
Shraddha Parate, Vikas Kumar, Gihwan Lee, Shailima Rampogu, Jong Chan Hong & Keun Woo Lee. (2021) Marine-Derived Natural Products as ATP-Competitive mTOR Kinase Inhibitors for Cancer Therapeutics. Pharmaceuticals 14:3, pages 282.
Crossref
Crossref
Ritu Karwasra, Surender Singh, Khalid Raza, Nitin Sharma & Saurabh Varma. (2021) A brief overview on current status of nanomedicines for treatment of pancytopenia: Focusing on chemotherapeutic regime. Journal of Drug Delivery Science and Technology 61, pages 102159.
Crossref
Crossref
Pradeep Ramalingam, Michael G. Poulos, Michael C. Gutkin, Lizabeth Katsnelson, Ana G. Freire, Elisa Lazzari & Jason M. Butler. (2020) Endothelial mTOR maintains hematopoiesis during aging. Journal of Experimental Medicine 217:6.
Crossref
Crossref
Jaimin Patel, Shaun A. Nguyen, Besim Ogretmen, Jorge S. Gutkind, Cherie‐Ann Nathan & Terry Day. (2020) mTOR inhibitor use in head and neck squamous cell carcinoma: A meta‐analysis on survival, tumor response, and toxicity. Laryngoscope Investigative Otolaryngology 5:2, pages 243-255.
Crossref
Crossref
Dorothy M K Keefe & Emma H Bateman. (2019) Potential Successes and Challenges of Targeted Cancer Therapies. JNCI Monographs 2019:53.
Crossref
Crossref
Georg Maschmeyer, Julien De Greef, Sibylle C. Mellinghoff, Annamaria Nosari, Anne Thiebaut-Bertrand, Anne Bergeron, Tomas Franquet, Nicole M. A. Blijlevens & Johan A. Maertens. (2019) Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia 33:4, pages 844-862.
Crossref
Crossref
Vasilios Karavasilis, Epaminontas Samantas, Georgia-Angeliki Koliou, Anna Kalogera-Fountzila, George Pentheroudakis, Ioannis Varthalitis, Helena Linardou, Grigorios Rallis, Maria Skondra, Georgios Papadopoulos, George Papatsibas, Joseph Sgouros, Athina Goudopoulou, Konstantine T. Kalogeras, Christos Dervenis, Dimitrios Pectasides & George Fountzilas. (2018) Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study. Targeted Oncology 13:6, pages 715-724.
Crossref
Crossref
R. ter Heine, N. P. van Erp, H. J. Guchelaar, J. W. de Fijter, M. E. J. Reinders, C. M. van Herpen, D. M. Burger & D. J. A. R. Moes. (2018) A pharmacological rationale for improved everolimus dosing in oncology and transplant patients. British Journal of Clinical Pharmacology 84:7, pages 1575-1586.
Crossref
Crossref
Kathleen N. Moore, Todd M. Bauer, Gerald S. Falchook, Swapan Chowdhury, Chirag Patel, Rachel Neuwirth, Aaron Enke, Fabian Zohren & Manish R. Patel. (2018) Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours. ESMO Open 3:2, pages e000291.
Crossref
Crossref
Teun van Gelder, Lutz Fischer, Fuad Shihab & Maria Shipkova. (2017) Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation. Transplantation Reviews 31:3, pages 151-157.
Crossref
Crossref
Demetrios Kalaitzidis, Dongjun Lee, Alejo Efeyan, Youmna Kfoury, Naema Nayyar, David B. Sykes, Francois E. Mercier, Ani Papazian, Ninib Baryawno, Gabriel D. Victora, Donna Neuberg, David M. Sabatini & David T. Scadden. (2017) Amino acid?insensitive mTORC1 regulation enables nutritional stress resilience in hematopoietic stem cells. Journal of Clinical Investigation 127:4, pages 1405-1413.
Crossref
Crossref
Gustav van Niekerk, Benjamin Loos, Theo Nell & Anna-Mart Engelbrecht. (2016) Cancer tolerance, resistance, pathogenicity and virulence: deconstructing the disease state. Future Oncology 12:11, pages 1369-1380.
Crossref
Crossref
YAPING ZHU, JIAQI SHEN, LIYAN GAO & YOUJI FENG. (2016) Estrogen promotes fat mass and obesity-associated protein nuclear localization and enhances endometrial cancer cell proliferation via the mTOR signaling pathway. Oncology Reports 35:4, pages 2391-2397.
Crossref
Crossref
Alfia Khaibullina, Luis E.F. Almeida, Li Wang, Sayuri Kamimura, Edward C.C. Wong, Mehdi Nouraie, Irina Maric, Sarah Albani, Julia Finkel & Zenaide M.N. Quezado. (2015) Rapamycin increases fetal hemoglobin and ameliorates the nociception phenotype in sickle cell mice. Blood Cells, Molecules, and Diseases 55:4, pages 363-372.
Crossref
Crossref
Thomas E. Witzig, Craig ReederJing Jing HanBetsy LaPlantMary StensonHan W. Tun, William Macon, Stephen M. AnsellThomas M. HabermannDavid J. InwardsIvana N. MicallefPatrick B. JohnstonLuis F. PorrataJoseph P. ColganSvetomir MarkovicGrzegorz S. NowakowskiMamta Gupta. (2015) The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood 126:3, pages 328-335.
Crossref
Crossref
Bin Xu, Mao-Lin Li, Xiao-Dong Zuo, Shou-Fei Zhu & Qi-Lin Zhou. (2015) Catalytic Asymmetric Arylation of α-Aryl-α-diazoacetates with Aniline Derivatives. Journal of the American Chemical Society 137:27, pages 8700-8703.
Crossref
Crossref
Jacky ChungDaniel E. BauerAlireza GhamariChristopher P. NizziKathryn M. DeckPaul D. KingsleyYvette Y. YienNicholas C. HustonCaiyong ChenIman J. SchultzArthur J. DaltonJohannes G. WittigJames PalisStuart H. OrkinHarvey F. LodishRichard S. EisensteinAlan B. CantorBarry H. Paw. (2015)
The mTORC1/4E-BP pathway coordinates hemoglobin production with
L
-leucine availability
. Science Signaling 8:372.
Crossref
Crossref
Amy Chen, Li Chen, Abeer Al-Qaisi, Edward Romond, Mukta Awasthi, Vera Kadamyan-Melkumyan & Suleiman Massarweh. (2015) Everolimus-Induced Hematologic Changes in Patients With Metastatic Breast Cancer. Clinical Breast Cancer 15:1, pages 48-53.
Crossref
Crossref
Calvin J. Meaney. 2015. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
471
490
.